Phase 3 Recruiting Academic/Other
This phase III trial tests if gabapentin can prevent the need for opiate pain medication for mouth sores (oral mucositis) in patients undergoing treatment with chemotherapy and radiation for squamous cell carcinoma of the head and neck reg…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT06992427
Sites in Utah: - Farmington Health Center — Farmington, Utah
- University of Utah Sugarhouse Health Center — Salt Lake City, Utah
- Huntsman Cancer Institute/University of Utah — Salt Lake City, Utah
- South Jordan Health Center — South Jordan, Utah
Phase 3 Recruiting Industry
The purpose of this study is to compare anti-tumor activity of amivantamab in addition to pembrolizumab and carboplatin versus pembrolizumab, 5-fluorouracil (FU), and platinum therapy (carboplatin or cisplatin) in participants with refract…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT07276399
Sites in Utah: - Huntsman Cancer Institute — Salt Lake City, Utah
Phase 2 Recruiting Academic/Other
This phase II trial compares the effect of usual treatment of docetaxel chemotherapy plus trastuzumab, to ado-emtansine (T-DM1) in patients with HER2-postive salivary gland cancer that has come back (recurrent), that has spread from where …
Sponsor: NRG Oncology
NCT ID: NCT05408845
Sites in Utah: - Huntsman Cancer Institute/University of Utah — Salt Lake City, Utah
Phase 1, Phase 2 Recruiting Industry
This is a Phase 1/2 open-label, multi-center, multi-national study with an initial dose escalation part to determine the recommended Phase II dose (RP2D) of MCLA-158 single agent in patients with mCRC. The dose escalation part has been com…
Sponsor: Merus B.V.
NCT ID: NCT03526835
Sites in Utah: - Utah Cancer Specialists — Salt Lake City, Utah
- University of Utah Health Huntsman Cancer Hospital — Salt Lake City, Utah
Phase 1, Phase 2 Recruiting Industry
Study STX-478-101 (LY4064809) is a multipart, open-label, phase 1/2 study evaluating the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of STX-478 (LY4064809) in participants with advanced solid tumors with…
Sponsor: Eli Lilly and Company
NCT ID: NCT05768139
Sites in Utah: - START Mountain Region — West Valley City, Utah
Phase 1, Phase 2 Recruiting Industry
This is a Phase 1/2, open-label, multicenter study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics and anti-tumor activity of TER-2013 in patients with advanced solid tumors harboring AKT/PI3K/PTEN pathway alteratio…
Sponsor: Terremoto Biosciences Inc.
NCT ID: NCT07109726
Sites in Utah: - START Center for Cancer Research — West Valley City, Utah
Phase 1, Phase 2 Recruiting Industry
The purpose of this study is to determine safety and preliminary efficacy of amivantamab monotherapy, amivantamab in addition to pembrolizumab, amivantamab in addition to paclitaxel and amivantamab in addition to pembrolizumab and carbopla…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT06385080
Sites in Utah: - University of Utah Huntsman Cancer Institute — Salt Lake City, Utah
Phase 1, Phase 2 Recruiting Industry
This is a multicenter, open-label, Phase 1/2 study of orally administered VMD-928 monotherapy and in combination with pembrolizumab in adult subjects with advanced solid tumors or lymphoma that have progressed or are non responsive to avai…
Sponsor: VM Oncology, LLC
NCT ID: NCT03556228
Sites in Utah: - Utah Cancer Specialists (site 203) — Salt Lake City, Utah
Phase 1, Phase 2 Recruiting Industry
This is a first in human, open-label, multi-center Phase 1 / 2 study to evaluate the safety, tolerability, and initial efficacy of AU-007, also known as imneskibart, in patients with advanced solid tumors. AU-007 will be administered eithe…
Sponsor: Aulos Bioscience, Inc.
NCT ID: NCT05267626
Sites in Utah: - University of Utah - Huntsman Cancer Institute — Salt Lake City, Utah
Phase 1, Phase 2 Recruiting Industry
The primary purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK) and anti-tumor activity of GTAEXS617 (REC-617) in participants with advanced solid tumors.
Sponsor: Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
NCT ID: NCT05985655
Sites in Utah: - START Mountain Region — West Valley City, Utah
Phase 2 Recruiting Academic/Other
The goal of this study is to evaluate if a shorter course of therapy can improve the quality of life in patients receiving radiation therapy after trans-oral robotic surgery.
Sponsor: University of Utah
NCT ID: NCT07044635
Sites in Utah: - Huntsman Cancer Institute/University of Utah — Salt Lake City, Utah
Phase 1 Recruiting Industry
The main purpose of this study is to evaluate the safety and preliminary efficacy of CHS-114 in combination with toripalimab and/or other standard of care (SOC) compound(s) in participants with advanced or metastatic solid tumors.
Sponsor: Coherus Oncology, Inc.
NCT ID: NCT06657144
Sites in Utah: - Huntsman Cancer Institute, University of Utah — Salt Lake City, Utah
- START Mountain Region, LLC. — West Valley City, Utah
Phase 1 Recruiting Industry
This is a Phase 1a/1b, open-label, multicenter dose escalation and dose expansion clinical study to evaluate the safety, PK, immunogenicity and preliminary efficacy of IDE034 in participants with locally advanced/metastatic solid tumor typ…
Sponsor: IDEAYA Biosciences
NCT ID: NCT07503808
Sites in Utah: - START Mountain Region, LLC — West Valley City, Utah
Phase 1 Recruiting Industry
This is a first-in-human Phase 1b, 2-part, multicenter open-label clinical study to evaluate safety and efficacy of a Nectin-4 radiopharmaceutical (\[225Ac\]Ac-AKY-1189) in patients with locally advanced or metastatic solid tumors and to e…
Sponsor: Aktis Oncology, Inc.
NCT ID: NCT07020117
Sites in Utah: - Huntsman Cancer Institute — Salt Lake City, Utah
Phase 1 Recruiting Industry
A Phase 1, First in Human, Open-Label Multicenter Study to Evaluate ALX2004, an Antibody Drug Conjugate Targeting EGFR in Participants with Advanced or Metastatic Select Solid Tumors
Sponsor: ALX Oncology Inc.
NCT ID: NCT07085091
Sites in Utah: - ALX Center 4 — West Valley City, Utah
Phase 1 Recruiting Industry
The primary purpose of this study is to determine the safety, tolerability, and maximum tolerated dose (MTD) of EXS74539 (REC-4539) in participants with select solid tumors.
Sponsor: Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
NCT ID: NCT07517198
Sites in Utah: - START Mountain Region — West Valley City, Utah
Phase 1 Recruiting Academic/Other
This is a Phase I trial evaluating the safety of personalized radiation therapy based on levels of hypoxia identified on FMISO-PET and MRI. All patients will receive a baseline FMISO positron emission tomography (PET) and MRI to identify l…
Sponsor: University of Utah
NCT ID: NCT04846309
Sites in Utah: - Huntsman Cancer Institute — Salt Lake City, Utah
NA Recruiting Academic/Other
This cluster-randomized comparative effectiveness trial compares a technology-based supportive cancer care (SCC) approach with a redesigned team-based supportive cancer care (SCC) approach.
Sponsor: Stanford University
NCT ID: NCT05297734
Sites in Utah: - George E. Wahlen Department of Veterans Affairs Medical Center — Salt Lake City, Utah
NA Recruiting Academic/Other
This study will assess if the CARES (Cancer Advocacy, Resources, Education and Support) intervention improves time to start of treatment after diagnosis and time to treatment completion for solid tumors (ex: lung, head, neck, thyroid, cerv…
Sponsor: University of Colorado, Denver
NCT ID: NCT04916990
Sites in Utah: - Huntsman Cancer Institute at the University of Utah — Salt Lake City, Utah